Great to be recognized for our pioneering efforts in precision treatment of neurodevelopment and neuropsychiatric disorders in Labiotech.eu's top 18 Swiss biotech companies.
Stalicla on the radar…among the top 18 Swiss biotech companies to keep an eye on according to labiotech.eu… Thanking the team for their unwavering determination to make precision neurodevelopmental and neuropsychiatric disorder treatments a reality.
Transposon, a company in the Dementia Discovery Fund (DDF) (SV Health Investors-managed fund), shared that its drug candidate TPN-101 is the first progressive supranuclear palsy (PSP) treatment to reduce key biomarkers of neurodegeneration and neuroinflammation in a Phase 2 study. #neurodegenerativediseases #progressivesupranuclearpalsytreatment https://lnkd.in/gAqVFY8P
Biomedical R&D Scientist | Project Manager | Decoding multi-organ metabolic signals to treat rare neuromuscular diseases | Outdoor Enthusiast and Aspiring Thru-Hiker
This article provides a great summary of the most impactful clinical developments in muscular dystrophy therapies during 2023. Excited to see the results of some of these trials in 2024! https://lnkd.in/gtkCh-hb
🔬 Discover the hidden secrets of the Mighty Melanocytes! 🌈🧪 Did you know that melanocytes not only play a vital role in our skin but also impact our brain, lungs, and heart? 🤯 In our latest article, "Mysteries of the Mighty Melanocytes," we dive deep into the fascinating world of iPSC-derived melanocytes and how they can revolutionize skin disease research, drug toxicity testing, and even cell therapy development! 🌟 Join us on a journey to unravel the mysteries of these unique cells and learn how they can help us understand and combat various diseases. 🧬💪 Don't miss out on this eye-opening read! Click the link below to explore the incredible potential of melanocytes in shaping the future of medicine. 👇 #Melanocytes #SkinDiseaseResearch #CellTherapy #MedicalBreakthroughs #ScienceAndInnovation https://hubs.li/Q02515D_0 #3dcellculture #lifesciences #drugdiscovery #drugdevelopment #stemcells
How can we help drugs to cross the blood-brain barrier to more effectively treat neurological diseases? Through its collaborative model, the Wyss' Brain Targeting Program is discovering and developing new, safe brain transport shuttles and effective ways to test them. Both are now available for non-exclusive licensing. #BrainTargetingProgram #NeurodegenerativeDisease #DrugDelivery #Therapeutics #BrainResearch https://lnkd.in/eD53bvk4
In a brand new case study, Deshpande et al. discusses treatment of a patient with #Neurofibromatosis type 1 (NF1) whose developed malignancies https://lnkd.in/ei_X2G6S #casestudy #precisiononcology
Fosgonimeton demonstrated encouraging pro-cognitive effects in clinical trials, supporting its continued development for the treatment of #Parkinsons Disease. On the heels of #ADPD2024, Andrea Lobo, Ph.D. of Parkinson's News Today highlights our SHAPE Phase 2 #fosgonimeton results, its mechanism of action, and supporting preclinical data in her recent article. Read it here: https://bit.ly/4awTtoC
There's a critical need for predictive techniques that enable healthcare professionals to anticipate the disease trajectory of Mild Cognitive Impairment (MCI) at an early stage—when interventions and management hold the most potential for efficacy. This is precisely the pioneering and significant work being undertaken by our colleagues at CereMark Pharma. You can read more about their efforts in this informative article by MD+DI. https://lnkd.in/gfED4KEt #nuclearmedicine #neurodegeneration #neurodegenerativediseases
Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖
Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖
🚨 Breaking News: FDA Advisory Committee Meeting to Discuss Vertex’s EXA-CEL for Sickle Cell Treatment 🚨 The FDA has taken a significant step by convening an Advisory Committee (AC) meeting to deliberate on Vertex’s innovative treatment, EXA-CEL, aimed at combating sickle cell disease in patients aged 12 years and above experiencing recurrent vaso-occlusive crises. EXA-CEL represents a groundbreaking approach, utilizing CRISPR/Cas9 technology for editing patient hematopoietic stem and progenitor cells (HSPCs). This meeting is pivotal as it will closely examine Vertex’s analysis of off-target alterations post-editing and evaluate the safety assessment’s adequacy. 🔬 This decision underscores the FDA's commitment to thoroughly reviewing cutting-edge therapies and ensuring the safety and efficacy of novel treatments. For those impacted by sickle cell disease, this meeting could mark a turning point in treatment options and offer hope for a better quality of life. 👥 As we await the outcomes of this crucial meeting, let's acknowledge the relentless efforts of researchers and clinicians striving to revolutionize patient care. Stay tuned for more updates on this developing story. #HealthcareInnovation #SickleCellTreatment #FDADecision #Vertex #EXACEL #CRISPR #GeneEditing #PatientCar
Head of Business Development at Credent Partners ‣ Empowering Brands with Digital & Influencer Marketing WW
1moCongratulations! such an amazing accomplishmen.